Cargando…

Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria

The antibiotic pipeline continues to diminish and the majority of the public remains unaware of this critical situation. The cause of the decline of antibiotic development is multifactorial and currently most ICUs are confronted with the challenge of multidrug-resistant organisms. Antimicrobial mult...

Descripción completa

Detalles Bibliográficos
Autores principales: Bassetti, Matteo, De Waele, Jan J., Eggimann, Philippe, Garnacho-Montero, Josè, Kahlmeter, Gunnar, Menichetti, Francesco, Nicolau, David P., Paiva, Jose Arturo, Tumbarello, Mario, Welte, Tobias, Wilcox, Mark, Zahar, Jean Ralph, Poulakou, Garyphallia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7080151/
https://www.ncbi.nlm.nih.gov/pubmed/25792203
http://dx.doi.org/10.1007/s00134-015-3719-z
_version_ 1783507970779250688
author Bassetti, Matteo
De Waele, Jan J.
Eggimann, Philippe
Garnacho-Montero, Josè
Kahlmeter, Gunnar
Menichetti, Francesco
Nicolau, David P.
Paiva, Jose Arturo
Tumbarello, Mario
Welte, Tobias
Wilcox, Mark
Zahar, Jean Ralph
Poulakou, Garyphallia
author_facet Bassetti, Matteo
De Waele, Jan J.
Eggimann, Philippe
Garnacho-Montero, Josè
Kahlmeter, Gunnar
Menichetti, Francesco
Nicolau, David P.
Paiva, Jose Arturo
Tumbarello, Mario
Welte, Tobias
Wilcox, Mark
Zahar, Jean Ralph
Poulakou, Garyphallia
author_sort Bassetti, Matteo
collection PubMed
description The antibiotic pipeline continues to diminish and the majority of the public remains unaware of this critical situation. The cause of the decline of antibiotic development is multifactorial and currently most ICUs are confronted with the challenge of multidrug-resistant organisms. Antimicrobial multidrug resistance is expanding all over the world, with extreme and pandrug resistance being increasingly encountered, especially in healthcare-associated infections in large highly specialized hospitals. Antibiotic stewardship for critically ill patients translated into the implementation of specific guidelines, largely promoted by the Surviving Sepsis Campaign, targeted at education to optimize choice, dosage, and duration of antibiotics in order to improve outcomes and reduce the development of resistance. Inappropriate antimicrobial therapy, meaning the selection of an antibiotic to which the causative pathogen is resistant, is a consistent predictor of poor outcomes in septic patients. Therefore, pharmacokinetically/pharmacodynamically optimized dosing regimens should be given to all patients empirically and, once the pathogen and susceptibility are known, local stewardship practices may be employed on the basis of clinical response to redefine an appropriate regimen for the patient. This review will focus on the most severely ill patients, for whom substantial progress in organ support along with diagnostic and therapeutic strategies markedly increased the risk of nosocomial infections. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00134-015-3719-z) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7080151
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-70801512020-03-23 Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria Bassetti, Matteo De Waele, Jan J. Eggimann, Philippe Garnacho-Montero, Josè Kahlmeter, Gunnar Menichetti, Francesco Nicolau, David P. Paiva, Jose Arturo Tumbarello, Mario Welte, Tobias Wilcox, Mark Zahar, Jean Ralph Poulakou, Garyphallia Intensive Care Med Review The antibiotic pipeline continues to diminish and the majority of the public remains unaware of this critical situation. The cause of the decline of antibiotic development is multifactorial and currently most ICUs are confronted with the challenge of multidrug-resistant organisms. Antimicrobial multidrug resistance is expanding all over the world, with extreme and pandrug resistance being increasingly encountered, especially in healthcare-associated infections in large highly specialized hospitals. Antibiotic stewardship for critically ill patients translated into the implementation of specific guidelines, largely promoted by the Surviving Sepsis Campaign, targeted at education to optimize choice, dosage, and duration of antibiotics in order to improve outcomes and reduce the development of resistance. Inappropriate antimicrobial therapy, meaning the selection of an antibiotic to which the causative pathogen is resistant, is a consistent predictor of poor outcomes in septic patients. Therefore, pharmacokinetically/pharmacodynamically optimized dosing regimens should be given to all patients empirically and, once the pathogen and susceptibility are known, local stewardship practices may be employed on the basis of clinical response to redefine an appropriate regimen for the patient. This review will focus on the most severely ill patients, for whom substantial progress in organ support along with diagnostic and therapeutic strategies markedly increased the risk of nosocomial infections. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00134-015-3719-z) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2015-03-20 2015 /pmc/articles/PMC7080151/ /pubmed/25792203 http://dx.doi.org/10.1007/s00134-015-3719-z Text en © Springer-Verlag Berlin Heidelberg and ESICM 2015 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Review
Bassetti, Matteo
De Waele, Jan J.
Eggimann, Philippe
Garnacho-Montero, Josè
Kahlmeter, Gunnar
Menichetti, Francesco
Nicolau, David P.
Paiva, Jose Arturo
Tumbarello, Mario
Welte, Tobias
Wilcox, Mark
Zahar, Jean Ralph
Poulakou, Garyphallia
Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria
title Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria
title_full Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria
title_fullStr Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria
title_full_unstemmed Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria
title_short Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria
title_sort preventive and therapeutic strategies in critically ill patients with highly resistant bacteria
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7080151/
https://www.ncbi.nlm.nih.gov/pubmed/25792203
http://dx.doi.org/10.1007/s00134-015-3719-z
work_keys_str_mv AT bassettimatteo preventiveandtherapeuticstrategiesincriticallyillpatientswithhighlyresistantbacteria
AT dewaelejanj preventiveandtherapeuticstrategiesincriticallyillpatientswithhighlyresistantbacteria
AT eggimannphilippe preventiveandtherapeuticstrategiesincriticallyillpatientswithhighlyresistantbacteria
AT garnachomonterojose preventiveandtherapeuticstrategiesincriticallyillpatientswithhighlyresistantbacteria
AT kahlmetergunnar preventiveandtherapeuticstrategiesincriticallyillpatientswithhighlyresistantbacteria
AT menichettifrancesco preventiveandtherapeuticstrategiesincriticallyillpatientswithhighlyresistantbacteria
AT nicolaudavidp preventiveandtherapeuticstrategiesincriticallyillpatientswithhighlyresistantbacteria
AT paivajosearturo preventiveandtherapeuticstrategiesincriticallyillpatientswithhighlyresistantbacteria
AT tumbarellomario preventiveandtherapeuticstrategiesincriticallyillpatientswithhighlyresistantbacteria
AT weltetobias preventiveandtherapeuticstrategiesincriticallyillpatientswithhighlyresistantbacteria
AT wilcoxmark preventiveandtherapeuticstrategiesincriticallyillpatientswithhighlyresistantbacteria
AT zaharjeanralph preventiveandtherapeuticstrategiesincriticallyillpatientswithhighlyresistantbacteria
AT poulakougaryphallia preventiveandtherapeuticstrategiesincriticallyillpatientswithhighlyresistantbacteria